CAMP4 Therapeutics (NASDAQ:CAMP) Shares Cross Above Fifty Day Moving Average - Should You Sell?

CAMP4 Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CAMP4 shares crossed above their 50-day moving average, trading as high as $4.08 and last at $3.86; the 50-day average is $3.85.
  • Analysts’ consensus rating is “Moderate Buy,” with a $10.44 average price target. Recent recommendations range from a $10 target at Raymond James to a raised $15 target at Piper Sandler.
  • The company reported a quarterly loss of $0.37 per share, missing the $0.20 loss analysts expected. Insiders sold about 593,600 shares over three months, although CFO Kelly Gold separately bought 10,000 shares.
  • Interested in CAMP4 Therapeutics? Here are five stocks we like better.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.85 and traded as high as $4.08. CAMP4 Therapeutics shares last traded at $3.86, with a volume of 108,509 shares trading hands.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Zacks Research upgraded CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, August 17th. Raymond James Financial started coverage on CAMP4 Therapeutics in a research report on Friday, October 23rd. They issued a "strong-buy" rating and a $10.00 price objective for the company. Piper Sandler reiterated an "overweight" rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Wall Street Zen raised CAMP4 Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, November 7th. Finally, Chardan Capital lowered their price target on shares of CAMP4 Therapeutics from $6.50 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, CAMP4 Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.44.

Check Out Our Latest Report on CAMP4 Therapeutics

CAMP4 Therapeutics Price Performance

The business has a 50 day simple moving average of $3.85 and a 200 day simple moving average of $4.20. The company has a market cap of $242.22 million, a price-to-earnings ratio of -1.80 and a beta of 0.28.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The Wireless communications provider reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.17). CAMP4 Therapeutics had a negative return on equity of 182.39% and a negative net margin of 2,276.33%. The company had revenue of $1.90 million for the quarter. As a group, sell-side analysts anticipate that CAMP4 Therapeutics Corporation will post -0.78 earnings per share for the current fiscal year.

Insider Activity at CAMP4 Therapeutics

In related news, CFO Kelly Gold purchased 10,000 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the acquisition, the chief financial officer directly owned 10,000 shares in the company, valued at approximately $39,600. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Andrew Schwab sold 400,000 shares of the firm's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the sale, the director directly owned 2,033,270 shares of the company's stock, valued at approximately $8,214,410.80. This represents a 16.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 593,613 shares of company stock worth $2,504,037 over the last three months. 21.69% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CAMP. Jupiter Topco LLC acquired a new position in CAMP4 Therapeutics during the 2nd quarter valued at about $27,581,000. 5AM Venture Management LLC bought a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $25,647,928. Trails Edge Capital Partners LP acquired a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $8,446,935. BlackRock Inc. bought a new stake in shares of CAMP4 Therapeutics during the second quarter worth approximately $7,185,000. Finally, Integral Health Asset Management LLC bought a new stake in shares of CAMP4 Therapeutics during the third quarter worth approximately $2,000,000.

About CAMP4 Therapeutics

(Get Free Report)

CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company's research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CAMP4 Therapeutics Right Now?

Before you consider CAMP4 Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CAMP4 Therapeutics wasn't on the list.

While CAMP4 Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines